Technology area: Medical Devices & Mechanical Engineering
2 pending office actions • 1 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready
Sigyn Therapeutics Inc. currently manages 2 pending office actions in the Medical Devices & Mechanical Engineering technology area. These matters are assigned to distinct examiners, ensuring that the company's prosecution is not overly dependent on any single official. The actions are contained within 1 distinct art unit, which indicates a consistent technical focus for the pending applications.
ADAM M MARCETICH is the busiest examiner for the portfolio, overseeing 1 pending office action. Because the busiest examiner pending count is only half of the 2 total pending office actions, the company must manage multiple separate lines of communication with the patent office. The distribution of one action per examiner across the single art unit requires the company to manage two separate professional relationships while adhering to the specific standards of a single technical group. Practitioners should monitor the specific trends within this art unit to ensure a cohesive strategy for the medical device innovations.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 2 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| MARCETICH, ADAM M | 1 | 72.8% | +18.8% |
| STRACHAN, KATE ELIZABETH | 1 | 49.6% | +31.5% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18827495 | DEVICES, SYSTEMS AND METHODS FOR THE BROAD-SPECTRUM REDUCTION OF PRO-INFLAMMATORY CYTOKINES IN BLOOD | MARCETICH, ADAM M | — |
| 18802722 | EXTRA-LUMEN ADSORPTION OF VIRAL PATHOGENS FROM BLOOD | STRACHAN, KATE ELIZABETH | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18827495 | DEVICES, SYSTEMS AND METHODS FOR THE BROAD-SPECTRUM REDUCTION OF PRO-INFLAMMATORY CYTOKINES IN BLOOD | MARCETICH, ADAM M | — |
| 18802722 | EXTRA-LUMEN ADSORPTION OF VIRAL PATHOGENS FROM BLOOD | STRACHAN, KATE ELIZABETH | — |
| Art Unit | Apps |
|---|---|
| 3781 | 2 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18827495 | DEVICES, SYSTEMS AND METHODS FOR THE BROAD-SPECTRUM REDUCTION OF PRO-INFLAMMATORY CYTOKINES IN BLOOD | MARCETICH, ADAM M | 3781 | §103§112 | Non-Final OA | — | Pending | Sep 06, 2024 |
| 18802722 | EXTRA-LUMEN ADSORPTION OF VIRAL PATHOGENS FROM BLOOD | STRACHAN, KATE ELIZABETH | 3781 | §102§103 | Non-Final OA | — | Pending | Aug 13, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialSigyn Therapeutics Inc. has 2 pending office actions as of October 2026, spread across 1 art units and 2 examiners.
Adam M Marcetich has the most, with 1 of Sigyn Therapeutics Inc.'s pending office actions.
Mostly Medical Devices & Mechanical Engineering (USPTO Tech Center 3700), based on where its pending office actions are examined.
